Welcome to our dedicated page for Eloxx Pharmaceut news (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceut stock.
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing RNA-modulating therapies for rare genetic disorders caused by nonsense mutations. This page provides authorized news updates and official announcements regarding clinical developments, regulatory milestones, and corporate progress.
Investors and stakeholders will find timely updates on key initiatives including clinical trial results, FDA designations, and research collaborations. Our curated news collection covers essential categories:
• Clinical program advancements for lead candidates ELX-02 and ZKN-013
• Regulatory updates including Orphan Drug Designations
• Strategic partnerships in genetic therapy development
• Financial disclosures and corporate communications
All content is sourced directly from company filings and verified press releases. Bookmark this page for reliable updates on Eloxx's innovative approach to addressing unmet needs in rare diseases through targeted RNA modulation therapies.
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced financial results for Q4 2022 and updates on ongoing clinical trials. The company has commenced dosing patients in a Phase 2 trial of ELX-02 for Alport syndrome, showing an initial reduction in proteinuria in one patient. Topline results are anticipated in H1 2023, with expectations of progressing to a Phase 3 study. Eloxx also filed an IND application for ZKN-013 to treat recessive dystrophic epidermolysis bullosa (RDEB) and plans to develop it further for familial adenomatous polyposis (FAP). The company reported a net loss of $6.3 million for Q4 2022, down from $12.1 million a year prior, and had cash reserves of $19.2 million as of year-end.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the submission of an Investigational New Drug (IND) application for ZKN-013 aimed at treating recessive Dystrophic Epidermolysis Bullosa (RDEB) with nonsense mutations. Currently, no approved treatments exist for RDEB and junctional epidermolysis bullosa (JEB). Preclinical data demonstrated up to an 18-fold increase in functional COL VII protein levels, supporting ZKN-013's efficacy. Additionally, an IND for familial adenomatous polyposis (FAP) is anticipated in the first half of 2023. Eloxx's efforts leverage its novel TURBO-ZM™ technology platform to develop therapies for rare diseases.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13, 2023, at 12:00 PM ET. A live webcast and replay of the presentation will be accessible on their website.
The company focuses on ribosomal RNA-targeted genetic therapies and is advancing its lead candidate, ELX-02, through Phase 2 clinical trials for treating Alport syndrome linked to nonsense mutations. Eloxx is also engaged in preclinical efforts targeting rare diseases, including specific cancers and kidney disorders. For more details, visit www.eloxxpharma.com.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the dosing of first patients in its Phase 2 study of ELX-02 for Alport syndrome targeting nonsense mutations. This disease lacks effective treatment options, and the trial aims to enroll up to eight patients, with dosing set for two months and follow-up for three months. Key endpoints include safety and reduction in proteinuria. Topline results are expected in the first half of 2023, with the company emphasizing the potential of ELX-02 based on previous preclinical data.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has initiated its Phase 2 clinical trial for ELX-02, targeting Alport syndrome in patients with nonsense mutations. The trial has commenced with the first patient enrollments, and topline results are anticipated in the first half of 2023. The trial aims to assess safety and efficacy primarily through proteinuria measurement in up to eight patients over a two-month period. Eloxx has highlighted the drug's potential in restoring collagen production, citing preclinical success and previous clinical activity, establishing a foundation for its development in this underserved patient population.
Eloxx Pharmaceuticals announced a 1-for-40 reverse stock split, effective December 1, 2022, at 5:00 PM ET. The move aims to boost the share price to meet Nasdaq's minimum bid requirement, facilitating continued listing. Shareholders will automatically receive one new share for every 40 shares held, and no fractional shares will be issued. A cash payment will be made for any fractional shares. The reverse split is part of the company's broader strategy to enhance market position and investor confidence.
Eloxx Pharmaceuticals (NASDAQ: ELOX) initiated a proof-of-concept Phase 2 clinical trial of ELX-02 in eight patients with Alport syndrome, expecting topline results in H1 2023. They plan to file an IND application for ZKN-013 for RDEB by early 2023. The company reported a Q3 2022 net loss of $7.5 million, an improvement from $9.9 million the previous year, aided by reduced R&D and G&A expenses. Cash reserves of $24.6 million are projected to sustain operations through Q4 2023, pending compliance with lender covenants.
Eloxx Pharmaceuticals, a leader in genetic therapies, has opened clinical trial sites in Australia and the UK for its Phase 2 study of ELX-02, targeting Alport syndrome in patients with nonsense mutations. This study aims to recruit up to eight patients and assess safety and protein levels in the kidney, with results expected in early 2023. Alport syndrome affects kidney function and has no current treatment options for those with nonsense mutations, which comprise about 6-7% of Alport patients.
